A.R.T. Advisors’s Viking Therapeutics VKTX Stock Holding History

A.R.T. Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-81,503	Closed	-$561K	–	1755
2019 Q3	$561K	Buy	+81,503	New	+$605K	0.03%	809
2019 Q1	–	Sell	-51,508	Closed	-$394K	–	1643
2018 Q4	$394K	Buy	51,508 +15,400	+43%	+$184K	0.03%	817
2018 Q3	$629K	Buy	36,108 +18,900	+110%	+$225K	0.03%	752
2018 Q2	$163K	Buy	+17,208	New	+$114K	0.01%	1262
2016 Q3	–	Sell	-20,300	Closed	-$25K	–	1167
2016 Q2	$25K	Buy	+20,300	New	+$26.8K	﹤0.01%	1293

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

A.R.T. Advisors's VKTX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Viking Therapeutics (VKTX) in Q4 2019, closing a stake of 81,503 shares — an estimated $561K sold.

A.R.T. Advisors first reported a position in VKTX in Q2 2016 and held it in 5 quarters. The position peaked at $629K in Q3 2018. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

A.R.T. Advisors reported no remaining Viking Therapeutics position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 81,503 Viking Therapeutics shares in Q4 2019, an estimated $561K.
A.R.T. Advisors first reported a position in Viking Therapeutics in Q2 2016 and held it in 5 quarters.
A.R.T. Advisors's Viking Therapeutics position peaked at $629K in Q3 2018.
143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.